Harp Dhaliwal serves as Chief Technical Operations Officer at Vaxcyte Inc., a clinical-stage biotechnology company pioneering next-generation protein vaccines to address unmet medical needs in immunology and oncology. In this pivotal role, Dhaliwal oversees the end-to-end technical operations, including process development, manufacturing, supply chain, and quality assurance for Vaxcyte's lead candidate, VAX-24, a broad-spectrum pneumococcal conjugate vaccine currently in Phase 3 trials. His leadership ensures scalable, high-quality production to support the company's ambitious clinical and commercial timelines, driving Vaxcyte's mission to transform vaccine innovation. With over 25 years of experience in the biopharmaceutical industry, Dhaliwal has held senior leadership positions at industry giants such as Genentech, where he directed large-scale mammalian cell culture manufacturing and tech transfers, and Amgen, managing global supply chain operations for blockbuster biologics. Earlier in his career, he contributed to process optimization at Pfizer and held technical roles at biotech startups, honing expertise in CMC development, regulatory compliance, and facility expansions. Dhaliwal holds a B.S. in Chemical Engineering from the University of California, Davis, and an M.S. in Biochemical Engineering from University College London. Dhaliwal's achievements include spearheading the successful scale-up of multiple commercial products, achieving FDA approvals for complex biologics, and implementing lean manufacturing strategies that reduced costs by up to 30% while maintaining stringent quality standards. At Vaxcyte, he has been instrumental in building a state-of-the-art manufacturing infrastructure, positioning the company for potential blockbuster success in pneumococcal disease prevention and beyond. His strategic vision continues to propel Vaxcyte's growth in the competitive vaccine landscape.